KDM1A and metabolic dysfunction-associated steatotic liver disease: These compelling findings provide evidence supporting the notion that the influence of KDM1A on NAFLD is dependent on its enzymatic activity, highlighting its potential as a promising therapeutic target for the treatment of NAFLD.